Virax Biolabs Group Limited (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today announced it has completed its initial public offering (IPO) and the Company’s shares began trading on July 21, 2022 on the Nasdaq Capital Market under the ticker symbol “VRAX.”
TAAD LLP provided accounting and financial reporting services for the Company as of and for the years ended March 31, 2021 and 2020.
The company’s IPO consisted of 1,350,000 ordinary shares at a public offering price of $5.00 per share, for total gross proceeds of $6.75 million, before deducting underwriting discounts, commissions, and other related expenses.
